m+Medelevator.RU
← Поиск публикаций
Journal of pharmacy & bioallied sciences · 2025

Comparison of Photodynamic Therapy (PDT) Using Methylene Blue and Toluidine Blue for the Treatment of Chronic Periodontitis- A Clinical and Microbiological Study.

СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Chungkham Sachidananda, Sambashivaiah Savita, Kulal Rithesh, Devi Ahanthem N

Аннотация

BACKGROUND: This research examined the efficiency of the two photosensitizers and assessed the efficacy of photodynamic therapy (PDT) using methylene blue and toluidine blue as supplements to scale and root planing (SRP) in the treatment of chronic periodontitis.

MATERIALS AND METHODS: Group I (SRP alone), group II (SRP + methylene blue-mediated PDT), and group III (SRP + toluidine blue-mediated PDT) included 30 patients with chronic periodontitis, each of whom had 10 members. At baseline, 1 month, and 3 months, clinical measures such as gingival index (GI), plaque index (PI), probing pocket depth (PPD), and clinical attachment level (CAL) were measured. Bacterial numbers were assessed by microbiological techniques.

RESULTS: From baseline to 1 and 3 months, all groups exhibited substantial improvements in clinical parameters and bacterial counts (P < 0.05). The groups did not, however, vary significantly from one another (P > 0.05). In conclusion, the clinical and microbiological results of photodynamic treatment with methylene blue or toluidine blue as adjuncts to SRP were similar to those of SRP alone.

CONCLUSION: The study's conclusions emphasize how crucial it is to understand how CIR, bone loss, and implant stability interact when designing restorations that are supported by implants. To confirm these findings and provide more solid recommendations for CIR in various therapeutic contexts, future studies with bigger sample numbers and longer follow-up times are advised.

ИП Урсолов Владлен Сергеевич

ИНН 500118482352 · ОГРНИП 314500117700049

Реквизиты и контакты